Bone Biologics shares surge 32.09% premarket after announcing 24-month shelf life extension for rhNELL-1, boosting manufacturing and commercialization readiness.

Bone Biologics (NASDAQ: BBLG) surged 32.09% in premarket trading following the announcement that its rhNELL-1 product’s shelf life has been extended to 24 months, a key operational milestone. The extension, validated by stability data and building on prior 12- and 18-month milestones, is expected to enhance manufacturing efficiency, supply-chain flexibility, and commercial readiness. The company emphasized that this achievement aligns with its long-term strategy to advance rhNELL-1 toward commercialization, improving inventory management and supporting disciplined capital deployment. CEO Jeff Frelick highlighted the milestone as a reflection of the company’s progress in executing development objectives, reinforcing confidence in the product’s potential for bone regeneration applications. The news, released on December 23, 2025, directly addresses operational and commercial challenges, positioning the stock for renewed investor optimism.